Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01725230 · ClinicalTrials.gov registry record · Phase 1
Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01725230 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 42 participants.
The verdict
NCT01725230, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
A study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin when administered alone or in combination with Fostamatinib.
Interventions
- DRUG Rosuvastatin
- DRUG Simvastatin
- DRUG Fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01725230
The ClinicalTrials.gov registry entry for NCT01725230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rosuvastatin is the first listed.
NCT01725230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01725230 about?
NCT01725230 is a clinical study titled "Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib". A study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin when administered alone or in combination with Fostamatinib.
What is the current status of trial NCT01725230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2012-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01725230?
The interventions under investigation include: Rosuvastatin (DRUG), Simvastatin (DRUG), Fostamatinib (DRUG).
Who is sponsoring clinical trial NCT01725230?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.